Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

People with diseases caused by rare mutations have fewer options and poorer prospects than other patients despite rapid ...